Two deaths are being reported to the U.S. Food and Drug Administration (FDA) as potentially linked to counterfeit versions of retatrutide, an investigational weight-loss medication that is not yet approved. CBS News reports that its investigation centers on the deaths being associated with “bootleg” retatrutide circulating online, and that details in the reports are still unverified.
The coverage comes as regulators and other authorities step up efforts to curb illicit sales of retatrutide and other popular weight-loss drugs. Outlets also note the broader context of legal disputes involving GLP-1 receptor agonists, with allegations that such medicines may cause serious adverse outcomes. While the current reports are framed as possible connections rather than confirmed causation, they highlight ongoing safety and enforcement concerns around unapproved and counterfeit products.
